Table 1.
In vivo limiting dilution assays of SPINK1 knockdown
| Huh7 | Tumor incidence | Average latency (Days) | Estimated TIC frequency | ||||
|---|---|---|---|---|---|---|---|
| Primary implantation | |||||||
| Cell numbers | 5k | 10k | 50k | 5k | 10k | 50k | |
| NTC | 5/8 | 4/8 | 6/8 | 31.9 | 32.6 | 25 | 1/18262 |
| SH2 | 1/8 | 1/8 | 0/8 | 34.1 | 34.8 | - | 1/256230 (p = 8.36e-6) |
| SH3 | 1/8 | 3/8 | 3/8 | 34.1 | 33.3 | 33.6 | 1/59524 (p = 0.0444) |
| Secondary implantation | |||||||
| Cell numbers | 5k | 10k | 5k | 10k | |||
| NTC | 10/14 | 13/14 | 20.3 | 19.1 | 1/3897 | ||
| SH2 | 3/14 | 6/14 | 24.4 | 22 | 1/18836 (p = 5.63e-5) | ||
| SH3 | 10/14 | 7/14 | 19.8 | 22.5 | 1/8271 (p = 0.0437) | ||
In vivo limiting dilution assays, in serial passage, for evaluating tumor-initiating cells (TICs) frequency of Huh7 cells with either non-target scrambled control (NTC) or SPINK1 knockdown lentiviral transduction (SH2 and SH3). Tumor incidence, average latency and estimated tumor-initiating frequency data. n = 4 mice for primary implantation; n = 7 mice for secondary implantation. Significance was calculated by one-sided Pearson’s χ2 test comparison to NTC.